Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody

Neoplasma

Volumn 50, Issue 1, 2003, Pages 13-21

  Chrastina, A ^a   Pastorekova S ^a   Pastorek, J ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Biodistribution; CA IX; Cervical cancer; Hypoxia; M75 monoclonal antibody; Tumor targeting

Indexed keywords

1,10 PHENANTHROLINE; CARBONATE DEHYDRATASE IX; COBALT; DEFEROXAMINE; ISOENZYME; MANGANESE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M75 I 125; NICKEL; SODIUM SULFATE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CARCINOMA;

EID: 0037270299     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. ACKER H, CARLSSON J, HOLTERMANN G, NEDERMAN T, NYLEN T. Influence of glucose and buffer capacity in the culture medium on growth and pH in spheroids of human thyroid carcinoma and human glioma origin. Cancer Res 1987; 47: 3504-3508.
2. BEASLEY NJ, WYKOFF CC, WATSON PH, LEEK R, TURLEY H, GATTER K, PASTOREK J, COX GJ, RATCLIFFE P, HARRIS AL. Carbonic anhydrase IX, an endogenous hypoxia marker: expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001; 61: 5262-5267.
3. BREWER CA, LIAO SY, WILCZYNSKI SP, PASTOREKOVÁ S, PASTOREK J, ZAVADA J, KUROSAKI T, MANETTA A, BERMAN ML, DISAIA PJ, STANBRIDGE EJ. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecologic Oncology 1996; 63: 337-344.
4. BRIZEL DM, SIBLEY GS, PROSNITZ LR, SCHER RL, DEWHRIST MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
5. BYSTRICKÁ M, VANČÍKOVÁ M, KASALOVÁ M, RUSS G, RAJČÁNI J, KOŠŤÁL M, POLÁKOVÁ K. Type - common and type - specific monoclonal antibodies to Herpes simplex virus type 1 and 2. Acta Virol 1991; 35: 152-164.
6. CHEN FM, TAYLOR CR, EPSTEIN AL. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989; 49: 4578-4585.
7. COSTA MJ, NDOYE A, TRELFORD JD. MN protein immunolocalization in uterine cervix carcinoma with glandular differentiation. A clinicopathologic study of a new cancer-specific biomarker. Int J Surg Pathol 1995; 3: 73-82.
8. DENARDO SJ, KROGER LA, DENARDO GL. A new era for radiolabeled antibodies in cancer? Curr Opin Imunol 1999; 11: 563-569.
9. 18F]EF5, a marker for PET detection of hypoxia: synthesis of precursor and new fluorination procedure. Applied Radiation and Isotopes 2001; 54: 73-80.
10. EHLEBEN W, PORWOL T, FANDREY J, KUMMER W, ACKER H. Cobalt and desferrioxamine reveal crucial members of the oxygen sensing pathway in HepG2 cells. Kidney Int 1997; 51: 483-491.
11. FYLES A, MILOSEVIC M, HEDLEY D, PINTILIE M, LEVIN W, MANCHUL L, HIL RP. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002; 20: 610-615.
12. GOLDBERG MA, DUNNING SP, BUNN HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1998; 242: 1412-1415.
13. HEMMERLEIN B, KUGLER A, OZISIK R, RINGERT R-H, RADZUN H-J, THELEN P. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch 2001; 439: 645-652.
14. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993; 26: 45-50.
15. HOCKEL M, SCHLENGER K, ARAL B, MITZE M, SCHAFFER U, VAUPEL P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-4515.
16. HÖCKEL M, SCHLENGER K, HÖCKEL S, VAUPEL P. Hypoxic cervical cancers with low apoptotic index are highly agressive. Cancer Res 1999; 59: 4525-4528.
17. HUNTER WM. Radioimmunoassay. In: Weir DM, editor. Handbook of Experimental Immunology. Blackwell scientific publications, Oxford/London/Edinburgh/Melbourne, 1978: 14.1-14.40.
18. IVANOV SL, LIAO SY, IVANOVA A, DANILKOVITCH-MIAGKOVA A, TARASOVA N, WEIRICH G, MERRILL MJ, PROESCHOLDT MA, OLDFIELD EH, LEE J, ZAVADA J, WAHEED A, SLY W, LERMAN MI, STANBRIDGE EJ. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001; 158: 905-919.
19. JAFFAR M, WILIAMS KJ, STRATFORD IJ. Bioreductive and gene therapy approaches to hypoxic diseases. Advanced Drug Delivery Reviews 2001; 53: 217-228.
20. KALUZ S, KALUZOVÁ M, CHRASTINA A, OLIVE PL, PASTOREKOVÁ S, PASTOREK J, LERMAN MI, STANBRIDGE EJ. Lowered oxygen tension induces expression of the hypoxia marker MN/Carbonic anhydrase IX in the absence of hypoxia-inducible factor 1α stabilization. Cancer Res 2002; 62: 4469-4477.
21. KANAYA K, TSAI AL, KAMIZANI T. Cobalt- and nikel-binding property of cullin-2. Biochem and Biophys Res Com 2002; 290: 294-299.
22. 2 measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999; 53: 99-104.
23. LANDO D, PEET DJ, WHELAN DA, GORMAN JJ, WHITELAW ML. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002; 295: 858-861.
24. LIAO SY, BREWER C, ZÁVADA J, PASTOREK J, PASTOREKOVÁ S, MANETTA A, BERMANN ML, DISAIA PJ, STANBRIDGE EJ. Identification of MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994; 145: 598-609.
25. LIAO SY, STANBRIDGE EJ. Expression of MN antigen in cervical Papanicolaou smears is an early diagnostic biomarker of cervical dysplasia. Cancer Epidemiology, Biomarkers and Prevention 1996; 5: 549-557.
26. LIESKOVSKÁ J, OPAVSKÝ R, ŽÁČIKOVÁ L', GLASOVÁ M, PASTOREK J, PASTOREKOVÁ S. Study of in vitro conditions modulating expression of MN/CA IX protein in human cell lines derived from cervical carcinoma. Neoplasma 1999; 46: 17-23.
27. LINDMO T, BOVEN E, CUTTITTA F, FEDORKO J, BUNN PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77-98.
28. LONCASTER JA, HARRIS AL, DAVIDSON SE, LOGUE JP, HUNTER RD, WYCOFF CC, PASTOREK J, RATCLIFFE PJ, STRARFORD IJ, WEST CML. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 6394-6399.
29. 2. A way of selecting patients for hyperoxic treatment. Strahlenther Onkol 1996; 172 Suppl 2: 8-9.
30. OLIVE PL, AQUINO-PARSONS C, MACPHAIL SH, LIAO SY, RALEIGH JA, LERMAN MI, STANBRIDGE EJ. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001; 61: 8924-8929.
31. PASTOREKOVÁ S, PARKKILA S, PARKKILA AK, OPAVSKÝ R, ZELNÍK V, SAARNIO J, PASTOREK J. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementery DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997; 112: 398-408.
32. PASTOREKOVÁ S, ZÁVADOVÁ Z, KOŠŤÁL M, BABUŠÍKOVÁ O, ZÁVADA J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187: 620-626.
33. PISANI P, PARKIN DM, BRAY F, FERLAY J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
34. RESNICK M, LESTER S, TATE JE, SHEETS EE, SPARKS C, CRUM CP. Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia. Hum Pathol 1996; 27: 234-239.
35. ROFSTAD EK, SUNDFOR K, LYNG H, TROPÉ CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83: 354-359.
36. WRIGHT EA, HOWARD-FLANDERS P. The influence of oxygen on the radiosensitivity of mamalian tissues. Acta Radiol 1957; 48: 26-32.
37. WYKOFF CC, BEASLEY NJP, WATSON PH, TURNER KJ, PASTOREK J, SIBTAIN A, WILSON GD, TURLEY H, TALKS KL, MAXWELL PH, PUGH CW, RATCLIFFE PJ, HARRIS AL. Hypoxia inducible regulation of tumor associated carbonic anhydrases. Cancer Res 2000; 60: 7075-7083.
38. YEH MY, ROFFLER SR, YU MH. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Int J Cancer 1992; 51: 274-282.
39. YUAN CC, TSAIL C, LEE TW, NG HP, YEH SH. Radioimmunodetection of human cervical carcinoma xenograft by 111In-labeled monoclonal antibody Mab Cx-99. Int J Gynaecol Obstet 1995; 49 Suppl: S33-S38.
40. ZÁVADA J, ZÁVADOVÁ Z, PASTOREK J, BIESOVÁ Z, JEŽEK K, VELEK J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82: 1808-1813.